This pilot study is the first proof-of-principle attempt to predict treatment response survival outcome in a small cohort of melanoma patients receiving anti-PD1 immune checkpoint inhibitor therapy – based on their Nodal expression profile. Here, PDCD1 is linked to melanoma.